[MO45] Mini-Oral Session 45　Lung Cancer / Thoracic Cancer 8（EGFR-TKI 2）
【E】

[MO45-2] First-line osimertinib for EGFR-mutated advanced NSCLC in elderly patients with poor performance status (HOT2002)

^○Yosuke Kawashima¹, Gaku Yamamoto², Hajime Asahina², Osamu Honjo³, Toshiyuki Sumi⁴, Kenichiro Ito⁵, Hajime Kikuchi⁶, Fumihiro Hommura⁷, Ryoichi Honda⁸, Keiki Yokoo⁹, Yuka Fujita¹⁰, Satoshi Oizumi¹¹, Ryo Morita¹², Yasuyuki Ikezawa¹³, Hisashi Tanaka¹⁴, Nozomu Kimura¹⁵, Taichi Takashina¹⁶, Toshiyuki Harada¹⁷, Hirotoshi Dosaka-Akita¹⁸, Hiroshi Isobe⁵ (1.Sendai Kousei Hospital, 2.Department of Respiratory Medicine, Hokkaido University Graduate School of Medicine, 3.Sapporo Minami Sanjo Hospital, 4.Hakodate Goryoukaku Hospital, 5.KKR Sapporo Medical Center, 6.Obihiro-Kosei General Hospital, 7.Sapporo City General Hospital, 8.Kokuho Asahi Chuo Hospital, 9.Teine Keijinkai Hospital, 10.National Hospital Organization Asahikawa Medical Center, 11.National Hospital Organization Hokkaido Cancer Center, 12.Akita Kousei Medical Center, 13.Oji General Hospital, 14.Hirosaki University Graduate School of Medicine, 15.Tohoku University Graduate School of Medicine, 16.Iwamizawa Municipal General Hospital, 17.JCHO Hokkaido Hospital, 18.Department of Medical Oncology, Hokkaido University Graduate School of Medicine)